Traderes Eye VIVUS (VVUS) Ahead of FDA PDUFA for its Rocket-Fire Viagra-Like Drug
Tweet Send to a Friend
Get Alerts VVUS Hot Sheet
Trade VVUS Now!
Shares of VIVUS Inc. (Nasdaq: VVUS) exploded higher in late-February after an FDA panel recommended approval for controversial obesity drug Qnexa, but now the company is in the spotlight again for an entirely different class of drug - erectile dysfunction.
VIVUS has an FDA action date of April 29, 2012 (Sunday) for its NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. Avanafil is in the same class as popular drugs Viagra, Levitra and Cialis but is faster acting with fewer side effects.
Trials showed avanafil can produce an erection in as little as 15 minute.
So, soon enough we will know if VIVUS's rocket-fire Viagra drug will be approved for those 50+ year old promiscuous men.
Shares of VVUS are up 1.9 percent in early action.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
VIVUS has an FDA action date of April 29, 2012 (Sunday) for its NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. Avanafil is in the same class as popular drugs Viagra, Levitra and Cialis but is faster acting with fewer side effects.
Trials showed avanafil can produce an erection in as little as 15 minute.
So, soon enough we will know if VIVUS's rocket-fire Viagra drug will be approved for those 50+ year old promiscuous men.
Shares of VVUS are up 1.9 percent in early action.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Yahoo! (YHOO) Board Said to Approve $1.1B Tumblr Deal
- VIVUS Announces Pricing of Offering of $220 Million of 4.50% Convertible Senior Notes
- Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
Create E-mail Alert Related Categories
FDA, Trader TalkComments
Approval Timelines
Can take forever and three days.
FDA
They do a great job.
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
FDA
David Dunlap on Apr 27, 2012 03:21 PMMark as Spam | Reply to this comment
needs and overhaul.